Genetic Variants (HIF1α , ACE I/D, STIM1, ORAI1 and TMPRSS6) on Erythropoietin Resistance in Dialysis Patients with Chronic Kidney Disease: Scoping Review

Authors

  • Linda Rosita Department of Clinical Pathology, Faculty of Medicine, Universitas Islam Indonesia, Yogyakarta, Indonesia and Doctoral Program, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada.
  • Nyoman Kertia Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada
  • Tri Ratnaningsih Department of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada
  • Vita Yanti Susanti Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada
  • Vita Widyasari Department of Public Health, Faculty of Medicine, Universitas Islam Indonesia
  • Rahma Yuantari Department of Clinical Pathology, Faculty of Medicine, Universitas Islam Indonesia

DOI:

https://doi.org/10.3329/bjms.v23i3.75016

Keywords:

Genetic Variants; EPO Therapy; Chronic kidney disease.

Abstract

Background Anemia is one of the most important chronic kidney disease (CKD) complications that usually managed with Erythropoietin Stimulating Agent (ESA). Some factors are responsible for ESA response included genetic predisposition. This review aimed to summarize variant genetics of HIF1α, ACE I/D, STIM1, ORAI1, and TMPRSS6 that are associated with EPO resistance in hemodialysis patients

Materials and Methods Seven databases were searched through Scopus, PubMed, Cochrane Library, Proquest, Science Direct, Wiley, and EBSCOhost to identify potential articles. The year of publication ranges from 2012 to 2022. The study included dialysis patients who defined measures for the erythropoietin resistance index (ERI), body weight, and hemoglobin (Hb). Synthesis is done by grouping according to thematic analysis for elaborative results.

Results and Discussion There are 2,712 articles in the initial registration, 7 articles met the eligible criteria. There were four studies about polymorphism of the ACE I/D gene, one study about minor alleles of STIMI and ORAI 1, one study about TMPRSS6, and one article study about HIF1α. ACE I/D polymorphisme showed some different effect, but patient with I/D allele tend to have lower Hb. STIM1 was associated with a lower risk of EPO resistance and ORAI1 was also associated with a higher risk of EPO resistance. The TMPRSS6 736V variant is associated with higher hepcidin levels in chronic hemodialysis patients.

Conclusion These study showed many genetic variants affect the success of EPO therapy with different mechanisms. Genetic variants recognized earlier than therapy may help predict the effectiveness and efficiency of EPO therapy.  

Bangladesh Journal of Medical Science Vol. 23 No. 03 July’24 Page : 626-631

Downloads

Download data is not yet available.
Abstract
239
PDF
349

Downloads

Published

2024-07-29

How to Cite

Rosita, L., Kertia, N., Ratnaningsih, T., Susanti, V. Y., Widyasari, V., & Yuantari, R. (2024). Genetic Variants (HIF1α , ACE I/D, STIM1, ORAI1 and TMPRSS6) on Erythropoietin Resistance in Dialysis Patients with Chronic Kidney Disease: Scoping Review. Bangladesh Journal of Medical Science, 23(3), 626–631. https://doi.org/10.3329/bjms.v23i3.75016

Issue

Vol. 23 No. 3 (2024)

Section

Review Article

License

Copyright (c) 2024 Linda Rosita, Nyoman Kertia, Tri Ratnaningsih, Vita Yanti Susanti, Vita Widyasari, Rahma Yuantari

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in the Bangladesh Journal of Medical Science agree to the following terms that:

  1. Authors retain copyright and grant Bangladesh Journal of Medical Science the right of first publication of the work.

  2. Creative Commons Licence
    Articles in Bangladesh Journal of Medical Science are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.
  3. Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  4. Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.